Abstract of Study Confirming Predictive Value of Vicor Technologies, Inc.' PD2i(R) for Cardiac Mortality Accepted for Presentation at American College of Cardiology 60th Annual Scientific Session

BOCA RATON, FL--(Marketwire - January 25, 2011) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that an abstract summarizing the results of a study involving the use of its PD2i® nonlinear algorithm and software to risk stratify congestive heart failure patients has been accepted for the American College of Cardiology 60th Annual Scientific Session and i2 Summit. Vicor Technologies (http://www.vicortech.com) is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, diabetics for the presence of diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

Wojciech Zareba, MD, PhD, a Professor of Medicine and Director of the Heart Research Follow-up Program at the University of Rochester Medical Center, will present "Prognostic Significance of PD2i, Novel Risk Marker in Heart Failure Patients" on Monday, April 4, 2011 at 3:30pm during the session titled "ECG/Ambulatory Monitoring - Prognosis in Heart Failure." The American College of Cardiology 60th Annual Scientific Session and i2 Summit will be held at the Ernest N. Morial Convention Center in New Orleans, LA on April 2-5, 2011.

Dr. Zareba was the Principal Investigator on a study titled "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," which was conducted under a collaborative agreement between Vicor Technologies, and the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona. The goal of the study was to evaluate the ability of Vicor's PD2i® nonlinear algorithm to predict cardiac events in the 537 chronic heart failure patients enrolled in the MUSIC Trial; MUSIC Trial participants were followed for an average period of 44 months. The conclusion of the University of Rochester researchers who conducted the study is that the PD2i® nonlinear algorithm and software is predictive of total mortality, cardiac death, and heart failure death in patients with left ventricular ejection fraction of less than or equal to 35%. With a hazard ratio of 2.34 and a P value of 0.023 for congestive heart failure mortality, a hazard ratio of 1.89 and a p value of .013 for cardiac mortality and a hazard ration of 1.95 and a p value of .004 for total mortality, the study results are highly statistically significant and demonstrated the ability of the PD2i Analyzer™ to identify those patients at an elevated risk of total mortality, cardiac mortality and congestive heart failure death. Commenting on the study and its results, Dr. Zareba said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Testing heart failure patients using the PD2i® should enhance risk stratification and motivate physicians to implant these devices in ICD/CRT-D eligible patients with abnormal PD2i® test results."

"We're extremely pleased and honored to have this abstract of our MUSIC Trial data study presented at the American College of Cardiology 60th Annual Scientific Session and i2 Summit by Dr. Zareba. While risk prediction is not an approved claim -- the data is under review by the FDA -- we believe the results achieved by the PD2i® nonlinear algorithm in this important study may broaden the market for its use as a diagnostic that will significantly contribute to cardiologists in their assessment of treatment options for heart failure patients. As we steadily advance commercialization of our PD2i® diagnostics, visibility at prestigious conferences such as this enhances our opportunity to explore new strategic relationships and collaborative efforts that may enable us to identify new applications for the PD2i. Additional information about the PD2i® nonlinear algorithm and trials demonstrating its use to identify those at risk of cardiac death -- along with information about how the PD2i® is being used to identify early-stage autonomic nervous system dysfunction and risk stratify trauma victims to improve triage efforts -- may be found at our website: www.vicortech.com," Mr. Fater concluded.

The American College of Cardiology (ACC) is a 39,000-member nonprofit medical society established in 1949 to advocate for quality cardiovascular care through education, research promotion, development and application of standards and guidelines, and to influence health care policy. ACC members are physicians, nurses, nurse practitioners, physician assistants, pharmacists and practice managers. The ACC's Annual Scientific Session and i2 (Innovation in Intervention) Summit features cutting-edge science, innovation, education, networking, intervention.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions, such as the American College of Cardiology, ACC Annual Scientific Session and i2 Summit, University of Rochester, and Catalan Institute of Cardiovascular Sciences in Barcelona, and the U.S. Army Institute for Surgical Research, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People's Republic of China; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-05

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: biotechnology medical diagnostics cardiac mortality congestive heart failure arrythmia ICD